Response to Attarian regarding article

S. Simpson,B. Taylor,I. van der Mei

DOI: https://doi.org/10.1111/ane.12597

2017-03-01

Acta Neurologica Scandinavica

Abstract:We write in response to the letter by Dr Attarian regarding our paper, ‘Anxiety, depression and fatigue at 5-year review following CNS demyelination (1)’ (ANE-L-01-16-055), published at Acta Neurologica Scandinavica. We greatly appreciate the kind words by Dr Attarian regarding our work and are delighted it has met with positive reception. With regard to his comments about the relevance of sleep disorders like obstructive sleep apnoea to fatigue and mood, we could not agree more. We had thought to examine this highly relevant parameter in our analysis, particularly of fatigue but also of mood, but unfortunately we did not have this data in a form that could be used. Participants were queried at baseline and subsequent reviews for being diagnosed with medical conditions aside from the demyelinating condition which brought them into the study, and to enumerate these in free-text form. Of the 279 AusLong participants with baseline data, four participants reported having been diagnosed with sleep apnoea, while in subsequent annual reviews 2/236 additional persons reported this diagnosis. We were loath to evaluate this variable quantitatively, however, because it was not systematically queried of participants but rather relied on passive reporting. Thus, it may very well be that other participants may have had this comorbidity and failed to report or recall at review. We would point out that our analysis of whether persons reported having any non-MS medical conditions diagnosed as the preceding review showed a positive association with both fatigue and anxiety and depression scores, and it is possible that part of this effect may have been persons with sleep-related comorbidities. Again, however, the failure to systematically query sleep precluded our evaluating it as a distinct covariate in this analysis. Certainly, future studies of mood and fatigue in multiple sclerosis would benefit from systematically assessing sleep quality and sleep-related conditions, as indeed these are quite relevant to these aspects of disease and quality of life in MS. We thank Dr Attarian for pointing out the importance of this element.